Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 4Cyclophosphamide 4pomalidomide 2pegylated granulocyte colony-stimulating factor 2pegfilgrastim 2fludarabine 2carfilzomib 2Etoposide 2Cytarabine 2Bortezomib 2fosaprepitant 1fludarabine phosphate 1daratumumab 1Zoledronic Acid 1Vaccination 1Tropisetron 1Thiotepa 1Renal Replacement Therapy 1Prednisone 1Pneumococcal Vaccines 1Olanzapine 1Melphalan 1Lenalidomide 1Granulocyte Colony-Stimulating Factor 1Cyclosporine 1Azacitidine 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Tropisetron × Plasma cell × Clear all
NCT07413809 2026-02-17

Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen

The Affiliated People's Hospital of Ningbo University

Phase 3 Recruiting
92 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡